Most documented safety issues reported during Enspryng (satralizumab-mwge) treatment for neuromyelitis optica spectrum disorder (NMOSD) in a real-world database have been consistent with the therapy’s reported safety profile in clinical trials, a study showed. Simultaneous use of corticosteroids, a common anti-inflammatory treatment in NMOSD, was associated with higher…
Discussion
Everyone has embarrassing moments from time to time, but a neuromyelitis optica spectrum disorder (NMOSD) embarrassing moment is on another level. One of these happened to me 16 years ago, during my first transverse myelitis attack, when I could no longer feel my bladder. You’d think that would…
For a rare group of neuromyelitis optica spectrum disorder (NMOSD) patients who test negative for two self-reactive antibodies, being older than 32 at disease onset may increase the risk of relapses, a study found. In contrast, spinal cord involvement, with or without optic nerve inflammation, at disease onset was…
NMOSD is a progressive autoimmune disease where the immune system mistakenly attacks nerve cells, affecting the nervous system. Learn more about the disease here.
Scientists do not know the exact underlying cause of NMOSD. Self-reactive antibodies that target AQP4 are known to play a major role. Learn more about what causes the disease here.
When the disease affects the optic nerve (optic neuritis), it can result in pain inside the eye and possibly blurry vision or vision loss. Learn more about the symptoms of the disease here.
Get regular updates to your inbox.
